In this review, we summarize the up-to-date understanding of the pathology and molecular features for Ewing sarcoma, and various EWSR1::FLI1 regulatory mechanisms especially post-translational modifications, aiming to provide new insights for identifying novel drug targets to fight against this deadly pediatric cancer. This evidence concerns the gene FLI1 and Ewing sarcoma.